|
US6258360B1
(en)
*
|
1989-05-04 |
2001-07-10 |
Igen International, Inc. |
Prodrugs activated by targeted catalytic proteins
|
|
US5527782A
(en)
*
|
1990-03-13 |
1996-06-18 |
Acic (Canada) Inc. |
5-halo-2,3'-O-cyclocytidines
|
|
TW254946B
(cs)
*
|
1992-12-18 |
1995-08-21 |
Hoffmann La Roche |
|
|
AU671491B2
(en)
*
|
1992-12-18 |
1996-08-29 |
F. Hoffmann-La Roche Ag |
N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
|
|
US5476932A
(en)
*
|
1994-08-26 |
1995-12-19 |
Hoffmann-La Roche Inc. |
Process for producing N4-acyl-5'-deoxy-5-fluorocytidine derivatives
|
|
IT1291983B1
(it)
*
|
1997-05-23 |
1999-01-25 |
Pro Bio Sint Srl |
Prodcedimento per la preparazione di un derivato della desossiuridina
|
|
NZ330360A
(en)
*
|
1997-06-02 |
1999-03-29 |
Hoffmann La Roche |
5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
|
|
EP0882734B1
(en)
*
|
1997-06-02 |
2009-08-26 |
F. Hoffmann-La Roche Ag |
5'-Deoxy-cytidine derivatives
|
|
US6005098A
(en)
*
|
1998-02-06 |
1999-12-21 |
Hoffmann-La Roche Inc. |
5'deoxycytidine derivatives
|
|
US20080113025A1
(en)
*
|
1998-11-02 |
2008-05-15 |
Elan Pharma International Limited |
Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
|
|
US20010051348A1
(en)
*
|
2000-01-28 |
2001-12-13 |
Lee Chee Wee |
Novel ligands and methods for preparing same
|
|
SE0102764D0
(sv)
|
2001-08-17 |
2001-08-17 |
Astrazeneca Ab |
Compounds
|
|
AU2003217676B2
(en)
|
2002-02-22 |
2009-06-11 |
Takeda Pharmaceutical Company Limited |
Active agent delivery systems and methods for protecting and administering active agents
|
|
US6774758B2
(en)
*
|
2002-09-11 |
2004-08-10 |
Kalyan P. Gokhale |
Low harmonic rectifier circuit
|
|
GB0226930D0
(en)
|
2002-11-19 |
2002-12-24 |
Astrazeneca Ab |
Chemical compounds
|
|
US20080026044A1
(en)
*
|
2003-05-20 |
2008-01-31 |
Jonathan Lewis |
Combination Chemotherapy Comprising Capecitabine and a Liposomal Platinum Complex
|
|
DK1706414T3
(da)
|
2003-12-22 |
2008-10-13 |
Hoffmann La Roche |
Fremgangsmåde til fluorcytidinderivater
|
|
WO2005080359A1
(en)
*
|
2004-02-18 |
2005-09-01 |
Astrazeneca Ab |
Benzamide derivatives and their use as glucokinae activating agents
|
|
EP1718625A1
(en)
*
|
2004-02-18 |
2006-11-08 |
AstraZeneca AB |
Compounds
|
|
CN100383128C
(zh)
*
|
2004-02-23 |
2008-04-23 |
上海迪赛诺医药发展有限公司 |
N4-氧羰基胞嘧啶衍生物及制备方法与应用
|
|
TW200600086A
(en)
|
2004-06-05 |
2006-01-01 |
Astrazeneca Ab |
Chemical compound
|
|
KR101061850B1
(ko)
|
2004-09-08 |
2011-09-02 |
삼성전자주식회사 |
박막 트랜지스터 표시판 및 그 제조방법
|
|
GB0421294D0
(en)
*
|
2004-09-24 |
2004-10-27 |
Angiogene Pharm Ltd |
Bioreductively-activated prodrugs
|
|
GB0423043D0
(en)
*
|
2004-10-16 |
2004-11-17 |
Astrazeneca Ab |
Compounds
|
|
MX2007004560A
(es)
|
2004-10-16 |
2007-06-08 |
Astrazeneca Ab |
Proceso para hacer compuestos de fenoxi benzamida.
|
|
AU2006210572B2
(en)
|
2005-02-03 |
2011-08-04 |
The General Hospital Corporation |
Method for treating gefitinib resistant cancer
|
|
NO322682B1
(no)
*
|
2005-03-18 |
2006-11-27 |
Clavis Pharma Asa |
Anvendelse av gemcitabinderivater for fremstilling av orale doseringsformer ved kreftbehandling, samt slike orale doseringsformer
|
|
EP1868608A2
(en)
*
|
2005-04-01 |
2007-12-26 |
F. Hoffmann-Roche AG |
Method for administration of capecitabine
|
|
WO2006125958A1
(en)
*
|
2005-05-24 |
2006-11-30 |
Astrazeneca Ab |
2-phenyl substituted imidazol [4 , 5b] pyridine/ pyrazine and purine derivatives as glucokinase modulators
|
|
TW200714597A
(en)
|
2005-05-27 |
2007-04-16 |
Astrazeneca Ab |
Chemical compounds
|
|
US20110053910A1
(en)
*
|
2005-07-09 |
2011-03-03 |
Mckerrecher Darren |
2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
|
|
NZ564608A
(en)
|
2005-07-09 |
2009-09-25 |
Astrazeneca Ab |
Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
|
|
EP2027113A1
(en)
*
|
2005-07-09 |
2009-02-25 |
AstraZeneca AB |
Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
|
|
CN100569790C
(zh)
*
|
2005-07-15 |
2009-12-16 |
上海奥锐特国际贸易有限公司 |
合成n4-酰基-5'-脱氧-5-氟胞苷衍生物的方法
|
|
CA2616008A1
(en)
*
|
2005-07-21 |
2007-01-25 |
Stefan Meuer |
Stabilized chlorite solutions in combination with fluoropyrimidines for cancer treatment.
|
|
US9202182B2
(en)
*
|
2005-08-11 |
2015-12-01 |
International Business Machines Corporation |
Method and system for analyzing business architecture
|
|
AR057854A1
(es)
|
2005-11-04 |
2007-12-19 |
Wyeth Corp |
Combinaciones antineoplasicas con inhibidor de mtor, herceptina y/o hki-272 (e)-n-{4-[3-cloro-4-(2-piridinilmetoxi) anilino]-3-ciano-7-etoxi-6-quinolinil}-4-(dimetilamino)-2-butenamida
|
|
TW200738621A
(en)
|
2005-11-28 |
2007-10-16 |
Astrazeneca Ab |
Chemical process
|
|
US20080085310A1
(en)
*
|
2006-10-06 |
2008-04-10 |
Maria Oksana Bachynsky |
Capecitabine rapidly disintegrating tablets
|
|
TW200825063A
(en)
|
2006-10-23 |
2008-06-16 |
Astrazeneca Ab |
Chemical compounds
|
|
SA07280576B1
(ar)
|
2006-10-26 |
2011-06-22 |
استرازينيكا ايه بي |
مركبات بنزويل أمينو سيكليل غير متجانسة بأعتبارها عوامل منشطة للجلوكوكيناز
|
|
CN100425617C
(zh)
*
|
2006-10-31 |
2008-10-15 |
浙江海正药业股份有限公司 |
一种含氟嘧啶类化合物烷氧羰酰化的方法
|
|
MX2009006729A
(es)
|
2006-12-21 |
2009-08-07 |
Astrazeneca Ab |
Nuevo compuesto cristalino util como activador de glk.
|
|
ITMI20070435A1
(it)
|
2007-03-05 |
2008-09-06 |
Innovate Biotechnology Srl |
2',3'-di-o-acil-5-fluoronucleosidi
|
|
BRPI0810067A2
(pt)
*
|
2007-04-20 |
2014-10-21 |
Reddys Lab Ltd Dr |
Processo para a preparação de capecitabina
|
|
EP2164856A1
(en)
*
|
2007-06-01 |
2010-03-24 |
Synthon B.V. |
Processes related to making capecitabine
|
|
US8741858B2
(en)
|
2007-09-21 |
2014-06-03 |
Zhongxu Ren |
Oligomer-nucleoside phosphate conjugates
|
|
US8022216B2
(en)
|
2007-10-17 |
2011-09-20 |
Wyeth Llc |
Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
|
|
WO2009088989A1
(en)
*
|
2008-01-03 |
2009-07-16 |
Plus Chemicals, S.A. |
Process for the preparation of capecitabine
|
|
WO2010008744A2
(en)
|
2008-06-17 |
2010-01-21 |
Wyeth |
Antineoplastic combinations containing hki-272 and vinorelbine
|
|
KR20110052676A
(ko)
|
2008-08-04 |
2011-05-18 |
아스트라제네카 아베 |
피라졸로[3,4]피리미딘-4-일 유도체 및 당뇨병 및 비만을 치료하기 위한 이의 용도
|
|
CN102202667A
(zh)
|
2008-08-04 |
2011-09-28 |
惠氏有限责任公司 |
4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
|
|
EP2370414A4
(en)
*
|
2008-12-02 |
2012-11-14 |
Reddys Lab Ltd Dr |
PREPARATION OF CAPECITABINE
|
|
EP2393472B1
(en)
*
|
2008-12-05 |
2019-06-05 |
NanoMed Holdings Pty Ltd |
Amphiphile prodrugs
|
|
CN101787066B
(zh)
*
|
2009-01-23 |
2013-07-31 |
高峰 |
阿糖胞苷衍生物及其在抗癌抗肿瘤中的用途
|
|
GB0902434D0
(en)
|
2009-02-13 |
2009-04-01 |
Astrazeneca Ab |
Chemical process
|
|
GB0902406D0
(en)
|
2009-02-13 |
2009-04-01 |
Astrazeneca Ab |
Crystalline polymorphic form
|
|
LT3000467T
(lt)
|
2009-04-06 |
2023-04-11 |
Wyeth Llc |
Krūties vėžio gydymo schema naudojant neratinibą
|
|
AR076221A1
(es)
*
|
2009-04-09 |
2011-05-26 |
Astrazeneca Ab |
Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad
|
|
WO2010116177A1
(en)
|
2009-04-09 |
2010-10-14 |
Astrazeneca Ab |
A pyrazolo [4,5-e] pyrimidine derivative and its use to treat diabetes and obesity
|
|
CN101875680B
(zh)
*
|
2009-04-28 |
2012-07-25 |
上海信旗医药科技有限公司 |
一种核苷类化合物及其制备方法和应用
|
|
US20110021769A1
(en)
*
|
2009-07-23 |
2011-01-27 |
Scinopharm Taiwan Ltd. |
Process for Producing Fluorocytidine Derivatives
|
|
PL2835053T3
(pl)
|
2010-03-12 |
2016-12-30 |
|
Terapia skojarzona do leczenia raka piersi
|
|
JP2015518705A
(ja)
|
2012-04-02 |
2015-07-06 |
モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. |
ヒト疾患に関連する生物製剤およびタンパク質の産生のための修飾ポリヌクレオチド
|
|
WO2013151665A2
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of proteins associated with human disease
|
|
KR102281288B1
(ko)
*
|
2012-09-26 |
2021-07-26 |
에프. 호프만-라 로슈 아게 |
환형 에터 피라졸-4-일-헤테로사이클릴-카복사마이드 화합물 및 이의 사용 방법
|
|
WO2014074725A1
(en)
*
|
2012-11-07 |
2014-05-15 |
Ohio State Innovation Foundation |
Substituted gemcitabine aryl amide analogs
|
|
CN105792830A
(zh)
*
|
2013-03-15 |
2016-07-20 |
Z·索 |
取代的吉西他滨双环酰胺类似物和使用其的治疗方法
|
|
US10138507B2
(en)
|
2013-03-15 |
2018-11-27 |
Modernatx, Inc. |
Manufacturing methods for production of RNA transcripts
|
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
US20160194625A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
|
CN103450301B
(zh)
*
|
2013-09-09 |
2015-09-09 |
南通大学 |
法尼基硫代水杨酸-核苷缀合物、其制备方法及其医药用途
|
|
SG11201602503TA
(en)
|
2013-10-03 |
2016-04-28 |
Moderna Therapeutics Inc |
Polynucleotides encoding low density lipoprotein receptor
|
|
RU2770081C2
(ru)
*
|
2016-06-28 |
2022-04-14 |
Селликс Био Прайвет Лимитед |
Композиции и способы для лечения рака
|
|
US11584733B2
(en)
|
2017-01-09 |
2023-02-21 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
|
WO2018129533A1
(en)
|
2017-01-09 |
2018-07-12 |
Shuttle Pharmaceuticals, Llc |
Selective histone deacetylase inhibitors for the treatment of human disease
|
|
CA3061621A1
(en)
|
2017-04-26 |
2018-11-01 |
Thomas I. Kalman |
Multitargeted nucleoside derivatives
|
|
US10435429B2
(en)
|
2017-10-03 |
2019-10-08 |
Nucorion Pharmaceuticals, Inc. |
5-fluorouridine monophosphate cyclic triester compounds
|
|
US11407723B2
(en)
|
2018-01-09 |
2022-08-09 |
Shuttle Pharmaceuticals, Inc. |
Selective histone deacetylase inhibitors for the treatment of human disease
|
|
WO2019139920A1
(en)
|
2018-01-10 |
2019-07-18 |
Nucorion Pharmaceuticals, Inc. |
Phosphor(n)amidatacetal and phosph(on)atalcetal compounds
|
|
US11427550B2
(en)
|
2018-01-19 |
2022-08-30 |
Nucorion Pharmaceuticals, Inc. |
5-fluorouracil compounds
|
|
CN111801339B
(zh)
*
|
2018-01-19 |
2025-06-24 |
纽科利制药公司 |
5-氟尿嘧啶化合物
|
|
BR112021001652A2
(pt)
*
|
2018-08-03 |
2021-05-04 |
Cellix Bio Private Limited |
composto e composição farmacêutica
|
|
CN109651467A
(zh)
*
|
2019-01-15 |
2019-04-19 |
齐鲁天和惠世制药有限公司 |
一种卡培他滨杂质及其制备方法
|
|
MX2022000573A
(es)
|
2019-07-17 |
2022-02-10 |
Nucorion Pharmaceuticals Inc |
Compuestos ciclicos de desoxirribonucleotido.
|
|
JP2023523415A
(ja)
|
2020-04-21 |
2023-06-05 |
リガンド・ファーマシューティカルズ・インコーポレイテッド |
ヌクレオチドプロドラッグ化合物
|
|
JP2023535225A
(ja)
|
2020-07-24 |
2023-08-16 |
ストランド セラピューティクス インコーポレイテッド |
改変ヌクレオチドを含む脂質ナノ粒子
|
|
EP4274846A1
(en)
|
2021-01-08 |
2023-11-15 |
Strand Therapeutics Inc. |
Expression constructs and uses thereof
|
|
CN119317430A
(zh)
|
2022-04-26 |
2025-01-14 |
斯特兰德生物科技公司 |
包含委内瑞拉马脑炎(vee)复制子的脂质纳米颗粒及其用途
|
|
WO2025193628A2
(en)
|
2024-03-09 |
2025-09-18 |
Aadigen, Llc |
Compositions for treating cancer with kras mutations and uses thereof
|